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Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in malignant cells,
including gliomas, and is currently in anticancer clinical trials. However, the full-length and tagged forms of TRAIL, unlike the
untagged ligand (soluble TRAIL (sTRAIL)), exhibits toxicity against normal cells. Here, we report the generation and testing of an
adenovirus (AdsTRAIL) that expresses untagged sTRAIL in an intracranial xenograft model and a human glioma organotypic
slice culture model. AdsTRAIL efﬁciently induced apoptosis in glioma cell lines, including those resistant to sTRAIL, but not in
normal human astrocytes (NHAs). It inhibited anchorage-independent glioma growth and exerted a bystander effect in transwell
assays. Intratumoral injections of AdsTRAIL in a rodent intracranial glioma model resulted in reduced tumor growth and
improved survival compared with Ad-enhanced green ﬂuorescent protein (EGFP)- or vehicle-treated controls without toxicity.
Human glioma organotypic slices treated with AdsTRAIL demonstrated apoptosis induction and caspase activation.
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Induction of apoptosis can be harnessed as a promising
therapeuticstrategyagainstcancerbecauseofitspotentialfor
selective elimination of abnormal or unwanted cells without
systemic toxicity. Tumor necrosis factor (TNF)-related apop-
tosis-inducing ligand (TRAIL) is a member of the TNF family
of cytokines that is expressed either as a membrane-bound
protein on active NK cells, T cells, and dendritic cells or
released as a soluble ligand after cleavage of the full-length
transmembrane protein;
1,2 in both forms, it induces apoptosis
by engaging death receptors 4 and 5, which are differentially
overexpressed on the surface of tumor cells compared
with non-tumor cells.
3,4 The resultant assembly of a death-
inducingsignalingcomplexcausescaspaseactivationbyboth
extrinsic and intrinsic apoptotic pathways.
5 The selective
induction of apoptosis in tumor cells, but not in non-tumor
cells, occurs by poorly deﬁned mechanisms likely related to
differencesin the signaling pathwaysin these cells
6and to the
preferential expression of decoy receptors 1 and 2 in normal
cells that prevent transduction of the death signal.
7,8
Preclinical reports of the potential for hepatotoxicity and
neurotoxicityraisedinitialconcernsaboutthetolerabilityofthe
agent in humans and delayed trials targeting TRAIL pathways
in patients with cancer.
9,10 However, subsequent reports
attributing this effect to tagged TRAIL, and not the untagged
version, allowed continued development of this agent.
11 On
the basis of these characteristics, clinical trials involving
systemic administration of either the extracellular portion of
the ligand or antibodies against the death receptors have
been initiated against human malignancies.
12
Local delivery of TRAIL can circumvent issues related
to systemic administration of the ligand, including delivery,
stability in circulation and ﬁrst-pass effects, particularly in
the case of locoregional tumors. We examined this paradigm
in malignant glioma, a highly aggressive but locoregional
primary brain tumor, which is non-metastatic and is charac-
terized by local recurrence, making locoregional therapies
of particular relevance. Previous studies using the full-length
version of the protein in various cancers including gliomas
were inconsistent in the reports of its efﬁcacy.
13–15 Given
that the soluble diffusible version of human TRAIL (sTRAIL)
has antitumor activity and is relatively selective for tumor
cells, we hypothesized that sustained locoregional production
of sTRAIL would induce apoptosis in gliomas, exert a
bystander effect in adjacent tumor cells, and result in a
survival beneﬁt without systemic toxicity. Here, we con-
structed and tested a non-replicating adenoviral construct
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www.nature.com/cddisthat expressed sTRAIL and demonstrated its activity against
gliomas in vitro, in a bioluminescent mouse intracranial
xenograft model, and in a novel ex vivo human glioma tissue
slice model.
Results
AdsTRAIL induces apoptosis in sTRAIL-sensitive and
-resistant glioma cells. Sensitivity to sTRAIL varies among
cell types and several glioma cell lines are resistant to
puriﬁed exogenous sTRAIL. Among the variety of factors that
can govern such resistance, the short half-life of exogenous
sTRAIL can limit the exposure and consequently the efﬁcacy
of the agent. We postulated that sustained expression of
the ligand by AdsTRAIL would overcome this limitation.
AdsTRAIL treatment caused reduced viability of several
glioma cell lines, but not of normal human astrocytes (NHAs);
these changes were most evident in D54, U251HF, LN229,
and U373 cells and less so in U87 and SNB19 cells
(Figure 1a). The sensitive cells demonstrated apoptotic
morphology in response to both puriﬁed sTRAIL and
AdsTRAIL; in contrast, U87 and SNB19 cells were
resistant to sTRAIL but sensitive to AdsTRAIL (Figure 1b).
Annexin V staining and ﬂow-cytometric analysis showed
a time-dependent increase in early apoptosis, which peaked
by 12h, followed by an increase in late apoptosis (Figure 1c).
We conﬁrmed that the increased cell death seen with
AdsTRAIL was not due to a nonspeciﬁc increase in cellular
sensitivity to sTRAIL in response to adenoviral transduction
of glioma cells; TRAIL-resistant glioma cell lines, U87 and
SNB19, transduced with Ad-enhanced green ﬂuorescent
protein (EGFP) remained resistant to sTRAIL, whereas when
transduced with AdsTRAIL they efﬁciently underwent apop-
tosis, conﬁrming that it was a direct effect of AdsTRAIL
(Figure 1d and Supplementary Figure 1).
Induction of apoptosis by AdsTRAIL is glioma speciﬁc
and spares normal astrocytes. To examine the basis for
differential induction of apoptosis by AdsTRAIL in glioma
cells, but not NHAs, we studied the components of the
extrinsic apoptosis pathway in U251HF cells; activation of
caspase 8 and caspase 3 was seen in a time-dependent
manner closely paralleled by poly ADP ribose polymerase
(PARP) cleavage (Figure 2a). In contrast, NHAs treated
with AdsTRAIL at 100 multiplicity of infection (MOI) for 24h
did not show activation of the extrinsic apoptotic pathway
(Figure 2b), supporting the possibility that the effects of
AdsTRAIL are likely speciﬁc to gliomas.
Figure1 (a)Variousgliomacelllinesweretreatedwith100MOIAdsTRAILorAdEGFPfortheperiodindicated,andthenumberofviablecellswasdeterminedbyaWST1
assay. The effects of AdsTRAIL were also assessed in NHAs. (b) Morphological changes after treatment with AdsTRAIL in glioma cells sensitive (D54 and U251HF) or
resistant (U87 and SNB19) to sTRAIL. (c) U251HF cells were transduced with AdsTRAIL (100 MOI) and harvested at the periods indicated. The cells were stained with
Annexin-V(0.6mg/ml) andPI (50mg/ml) and analyzedby ﬂow cytometry.(d) U87 and SNB19 cells transducedwith AdEGFP (100 MOI)were treated with sTRAIL(100ng/ml)
and analyzed 48h later for the apoptotic cells (sub-G1 fraction) using ﬂow cytometry. Untreated cells, cells treated with sTRAIL, and those transduced with AdsTRAIL were
used as controls (data shown as mean percent sub-G1 from two independent experiments; error bars indicate standard error of mean)
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Cell Death and DiseaseAdsTRAIL treatment inhibits anchorage-independent
growth of glioma cells. Anchorage-independent growth in
soft agar is considered to be a surrogate for in vivo tumori-
genesis for solid tumors. Using a standard soft agar colony
formation assay, D54 MG cells were treated with phosphate-
buffered saline (PBS), AdEGFP, or AdsTRAIL and assessed
for anchorage-independent growth. Colony formation was
assessed by phase-contrast microscopy after 12 days with-
out additional virus treatment and the number of colonies
counted (Figure 3a). Untreated and AdEGFP-treated
controls were seen to form numerous colonies, whereas
only a few colonies were formed by the AdsTRAIL-treated
cells (Figure 3b); these colonies were small and low in
cellularity.
AdsTRAIL exerts a bystander effect against gliomas.
Non-replicating adenoviruses engineered to express non-
secreted proteins will cause an antitumor effect only in the
cells transduced by the virus; adjacent cells that escape this
effect could repopulate the tumor. In contrast, an adenoviral
Figure 2 (a) Immunoblot analysis of extrinsic death pathway activation including cleavage of caspase 8, caspase 3, and PARP (arrows) in U251HF cells treated with
AdsTRAIL or sTRAIL for the periods indicated. Soluble TRAIL (sT)-treated cells were assessed as control. (b) Comparison between the effects of AdsTRAIL (AdsT) or
AdEGFP (AdE) upon caspase 8, caspase 3, and PARP in U251HF cells and NHAs. Cells were treated with 100 MOI of adenovirus and harvested at 24h
Figure 3 Colony-forming assay using D54 cells. (a) Cells were treated with AdEGFP or AdsTRAIL and plated in soft agar and allowed to grow as colonies. Colony
formation was monitored by phase-contrast and ﬂuorescent microscopy, and the number of colonies counted on day 12 after plating. (b) The number of colonies for each
treatment condition was counted by phase-contrast microscopy and plotted as colonies per high power ﬁeld
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Cell Death and Diseaseconstruct expressing a soluble ligand can exert a bystander
effect on the non-transduced cells, thus contributing to a ﬁeld
antitumor effect. To test this concept, we transduced TRAIL-
resistant human mesenchymal stem cells (hMSCs) with
AdsTRAIL in the upper chamber of a two-chamber transwell
experiment and plated TRAIL-sensitive U251HF cells in the
lower chamber. To control for the possibility that the virus
released from the hMSCs may cross the transwell and
directly affect U251HF cells in the lower chamber, we
transduced the hMSCs in the upper chamber with AdEGFP
and monitored the lower chamber for green ﬂuorescent cells.
AdsTRAIL-transduced hMSCs in the upper chamber did not
show any evidence of apoptosis either by morphological
appearance or by ﬂow-cytometric analysis for a sub-G1
fraction (Figure 4a). In contrast, the U251HF cells in the
lower chamber efﬁciently underwent apoptosis; the cells,
however, did not exhibit green ﬂuorescence, indicating that
the effects seen were not due to direct transfer of the
adenoviral construct across the transwell membrane. These
results were also conﬁrmed by ﬂow-cytometric analysis of the
cells in both chambers (Figure 4b) and strongly support the
possibility that AdsTRAIL induced a bystander effect by
diffusion of the soluble protein.
Effect of locally administered AdsTRAIL on survival in
an intracranial glioma xenograft model. AdsTRAIL was
engineered to express sTRAIL to achieve sustained
production of high levels of diffusible TRAIL in the tumor
vicinity and to more efﬁciently induce apoptosis in gliomas.
We tested this in a rodent bioluminescent intracranial glioma
xenograft model; U251HF cells stably transfected with a
luciferase-expressing construct were implanted using a
guide-screw method
16 into the forebrain of nude mice and
tumor growth was monitored by bioluminescence imaging.
Animals with conﬁrmed tumors were sorted on day 0 into
various treatment groups, ensuring equal distribution of
tumor sizes (Figure 5a). The animals were injected intra-
tumorally with PBS, AdEGFP, or AdsTRAIL approximately 7
days later using the same guide-screw utilized for tumor cell
implantation. Tumor growth was monitored at regular inter-
vals for the ﬁrst 28 days by quantitative bioluminescence
imaging. PBS- and AdEGFP-treated tumor showed progres-
sive increase in tumor size, whereas AdsTRAIL-treated cells
showed an overall reduction in bioluminescence intensity
over the period of 4 weeks, suggesting an antitumor effect
(Figure 5b). A subset of animals were killed at day 3 after
adenoviral injection and parafﬁn-embedded sections
generated from the tumor-bearing brains. Unlike PBS- and
AdEGFP-treated cells, AdsTRAIL-injected tumors showed
characteristic morphological evidence of apoptosis, including
small condensed nuclei and fragmented cells (Figure 5c); in
addition, immunohistochemical studies indicated caspase 3
activation and TUNEL positivity in situ, conﬁrming that the
changes were related to apoptosis. The remaining animals
were monitored up for side effects of the adenoviral injection
and for tumor-related morbidity, and followed up for survival
up to 4 months. Upon Kaplan–Meier analysis, no signiﬁcant
difference in survival was seen between PBS- and AdEGFP-
treated cells (P¼0.33). In contrast, animals treated with
AdsTRAIL had a signiﬁcantly increased survival compared
with those treated with either AdEGFP or PBS (log rank
P¼0.019) (Figure 5d). These results conﬁrm the efﬁcacy of
AdsTRAIL in inhibiting glioma growth in vivo by induction of
apoptosis, and consequently improve survival in an invasive
glioma xenograft model.
Ex vivo effects of AdsTRAIL in human glioma
organotypic slice cultures. Serially passaged cell lines
are subject to genetic drift that often limits their utility in
determining biological behavior and treatment response of
human gliomas. Preclinical studies that rely solely on testing
the effects of novel agents against such established cell lines
or in vivo tumors derived from them retain the limitation of the
cells. Although these limitations can be partly overcome by
Figure 4 Bystander effect of AdsTRAIL in gliomas cells. (a) TRAIL-resistant hMSCs (2 10
5 cells) were plated in the upper chamber of a six-well transwell plate and
transduced with AdEGFP50MOI or AdsTRAIL* (AdsTRAIL50MOIþAdEGFP5MOI). After 24h, U251HF (2 10
5 cells) were plated in the lower chamber. Changes in cell
morphology inthelowerchamberswereexaminedat 48hto identifyapoptoticcells.(b)U251cellsfromthelowerchamberof thetranswell experimentwereharvestedat 48h
and analyzed by ﬂow cytometry for the sub-G1 (apoptotic) fraction
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Cell Death and Diseasethe direct use of human tumor tissue in preclinical studies,
there are no models that currently allow such ex vivo studies
in cancer. To address this, we developed a novel human
glioma organotypic slice culture model based on similar
cultures of normal rodent brain slices used in neuro-
physiological studies,
17 which maintains genetic identity
with the patient’s tumor; this model was utilized to test the
effect of AdsTRAIL in viable human glioma tissue. Freshly
resected gliomas were processed to obtain organotypic
slices, which were then treated with PBS, AdEGFP, or
AdsTRAIL for up to 72h. The slices were harvested, ﬁxed in
formalin, and embedded in parafﬁn. Slides were generated
and used for immunohistochemical studies. Hematoxylin and
eosin (H&E)-stained sections of the untreated control slices
showed the characteristic features of malignant glioma.
Slices treated with AdsTRAIL showed the presence of
cells with condensed and pyknotic nuclei consistent with
apoptotic bodies; these cells showed positivity for adenoviral
hexon expression, indicating generation of viral protein in
the transduced cells. The slices were also positive for
cleaved caspase 3 (Figure 6a) and in situ TUNEL staining
(Figure 6b), indicating activation of caspases and DNA
fragmentation. In contrast, AdEGFP-treated cells, which also
showed hexon expression, did not show positivity for either
Figure 5 Effects of AdsTRAIL on survival in an intracranial glioma xenograft model: (a) U251HF cells were implanted in the right forebrain of nude mice and tumor
formation was determined by bioluminescence imaging; mice with conﬁrmed tumors were equally distributed based on tumor sizes into treatment groups on day 0 and
monitored for change in bioluminescent signal after treatment with PBS, AdEGFP, or AdsTRAIL over the period indicated. (b) Animals intratumorally injected with PBS,
AdEGFP,orAdsTRAILweremonitoredatregularintervalsfortheﬁrst28daysbyquantitativeassessmentofbioluminescenceasasurrogatefortumorgrowth.(c)Asubsetof
animals were killed at day 3 after adenoviralinjection and parafﬁn-embedded sections generatedfrom the tumor-bearingbrains. Morphology was studied using H&E staining;
immunohistochemical studies were used to examine cleaved caspase 3 and TUNEL positivity. Higher magniﬁcation of the H&E-stained tumor tissue is shown in the right
panel. (d) U251HF cells were implanted in the right forebrain of nude mice and, after conﬁrming tumor growth, intratumoral injection of PBS (dotted line), AdEGFP (dashed
line), or AdsTRAIL (solid line) was performed and the animals monitored for survival. Probability of overall survival was determined by Kaplan–Meier analysis and the
signiﬁcance of differences assessed by log rank test
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Cell Death and Diseasecleaved caspase 3 or TUNEL staining. To conﬁrm these
ﬁndings, the slices were disaggregated into single-cell
suspension after treatment, ﬁxed and stained with
propidium iodide, and analyzed by ﬂow cytometry for
evidence of apoptosis. AdsTRAIL-treated cells showed a
time-dependent increase in the sub-G1 fraction (Figure 6c).
These results provide direct evidence of the ability of
AdsTRAIL to induce apoptosis in human glioma tissue and
strongly suggest that a similar effect could be expected
in vivo if the agent is delivered to the tumor.
Effects of combining AdsTRAIL with therapeutic
approaches in human glioma slice cultures. Given that
most single-agent therapies have limited activity in patients
with malignant gliomas, we examined whether AdsTRAIL
could exhibit enhanced antitumor activity in combination with
agents currently in use or in trials against gliomas.
Organotypic human glioma slice cultures were generated
from three different patients who underwent tumor resection
for recurrent glioblastoma and were transduced with
AdsTRAIL (100 MOI), AdEGFP (100 MOI), or PBS. The
slices were then treated with an alkylator (temozolomide,
20mM), a histone deacetylase inhibitor (vorinostat, suberoyl-
anilide hydroxamic acid, 5mM) or a proteosome inhibitor
(MG132, 10mM). To adequately determine the effects of
combination, the slices were harvested 24h later (when the
effects of single-agent AdsTRAIL were minimal) by preparing
a single-cell suspension from the slices and analyzing the
cells for the sub-G1 (apoptotic) fraction. In all three samples,
the combination of AdsTRAIL with each of the agents
showed a supra-additive induction of apoptosis (Figure 7).
These results, although preliminary, are derived directly in
human glioma tissue and hence support the potential for
rational combinations of AdsTRAIL with various agents
currently being studied or used against gliomas.
Discussion
Defects in the apoptotic pathway are the hallmark of most
malignancies and are the target of various therapeutic
strategies.
18 However, given that survival and death path-
ways are shared by normal and tumor cells, differential
sensitization of tumor cells without affecting normal cells has
been the goal to avoid the issue of toxicity to normal tissue.
Unlike TNF and Fas apoptotic signaling pathways, TRAIL
and its receptors differentially induce apoptosis in cancer
cells compared with most normal cells, which has led to
subsequent clinical development of this agent as an
anticancer therapy.
19 These ﬁndings were also the basis
of our assessment of the efﬁcacy of the adenovirally
expressed soluble form of TRAIL against locoregional tumor
gliomas.
Adenoviral constructs expressing full-length TRAIL have
shown activity against various malignancies.
15,20 Results of
Figure 6 Effect of AdsTRAIL on human glioma organotypic slice cultures. Organotypic slice cultures were generated from freshly resected human glioma specimens and
the slices treated with PBS, AdEGFP, or AdsTRAIL (100 MOI) for 48h. (a) Parafﬁn-embedded slices were stained with H&E or immunostained with a cleaved caspase 3
antibody.ArrowsindicatepyknoticandfragmentedapoptoticbodiesintheH&Esectionsandpositivestainingforcleavedcaspase3.(b)InsituTUNELstainingofgliomaslices
witharrowsshowingpositivelystainedcellsinthelowerpanelandapoptoticcellsintheupperpanel.(c)Asingle-cellsuspensionwasgeneratedfromsliceculturestreatedwith
PBS,AdEGFP,orAdsTRAILandsubjectedtoﬂow-cytometricanalysis.Thetimecourseofappearanceofthesub-G1fractionindicatingapoptoticcellswasdeterminedforthe
periods indicated
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Cell Death and Diseasesimilar studies in gliomas have been less consistent.
Naumann et al.
13 reported the lack of efﬁcacy of adenovirally
expressed full-length TRAIL against glioma despite the
detection of protein in culture medium; these results are not
inconsistent with our results given that after intracellular
generation full-length TRAIL can either be membrane
bound or, if expressed in its full-length form, be unable to
engage death receptors until it is cleaved into its soluble
form. In contrast, Kim et al.
21 reported that full-length
TRAIL expressed by a replication-incompetent adenovirus
(AdhTRAIL) was active against gliomas both in vitro and
in vivo; in their study, intratumoral injection of AdhTRAIL
inhibited growth of intracranial gliomas in a mouse orthotopic
model compared with vector control, although the effect on
survival was not reported. Unlike these prior approaches, we
elected to generate an adenoviral construct expressing the
soluble form of TRAIL. Recombinant sTRAIL had previously
been reported to have antitumor activity without toxicity.
22 In
previous studies by our group, sTRAIL had activity against
glioma cells in vitro and demonstrated the interaction of the
death and survival pathways in modulating the apoptotic
response.
23 Additionally, Roth et al.
14 reported that direct
intratumoral injection of sTRAIL eliminated intracranial xeno-
graftswithoutneurotoxicityinamousemodel.Basedonthese
data, we postulated that sTRAIL, expressed in a sustained
manner by an adenoviral construct, would have the greatest
potential for effectively engaging death receptors to induce
apoptosisand a bystander effect in the largest numberof cells
in and around the intratumoral injection site; the results of our
study in an invasive orthotopic tumor model and in an ex vivo
human glioma model strongly support this possibility.
Several features make our study different from previous
studies of TRAIL, which used free ligand or adenoviral
constructs in gliomas. Compared with other studies of
sTRAIL, which used his-tagged sTRAIL,
14 we used untagged
sTRAIL and demonstrated that AdsTRAIL induced apoptosis
inbothsTRAIL-sensitiveand-resistantgliomacells,indicating
a greater potency of this agent compared with sTRAIL. This
increased efﬁcacy could potentially be due to the sustained
production of the ligand by the adenovirus construct com-
pared with exogenously added recombinant sTRAIL, which
has a relatively short half-life. Additionally, AdsTRAIL did not
induce apoptosis in NHAs in vitro, suggesting a differential
effect on tumor cells. The speciﬁcity to tumor cells was also
supported by the lack of neurotoxicity or systemic toxicity in
the mouse intracranial xenograft models. Data obtained by
using an agent similar to ours have been previously reported
by Kim et al., who demonstrated the efﬁcacy of an engineered
trimeric sTRAIL expressed using an adenoviral construct
(AdstTRAIL) in various malignant cell lines.
24 This study
demonstrated clearly the efﬁcacy of AdstTRAIL in vitro and
in vivo in gliomas. The limitations of this study included the
following: the in vitro studies in gliomas were conﬁned to a
single cell line, U87MG. The in vivo studies were not
conducted in an intracranial model, but in a mouse ﬂank
subcutaneous injection model, which has limited relevance as
a model of glioma. In addition, the U87 cells used in these
studiesformcircumscribednon-invasivetumorsunlikehuman
gliomas, thus limiting the extent to which these results could
beapplicabletothehumandisease.Lastly,althoughthestudy
demonstrated the efﬁcacy of AdstTRAIL in suppression of
tumor growth, the impact on survival was not presented. The
same group addressed some of these deﬁciencies in a
second study in which AdstTRAIL was tested in several
glioma cell lines and using an intracranial model; they clearly
demonstrated the efﬁcacy of this agent, which was superior to
that of bis-chloro-ethyl nitrosourea, an alkylator that is used in
therapy of gliomas.
25 However, this study also utilized the
non-invasive U87 glioma model, which forms very localized
and circumscribed tumors that could artifactually respond to
local therapies, again placing limitations on interpretations of
such data in the context of the highly invasive human gliomas.
Unliketheseandotherintracranialxenograftstudiesthatused
U87MG cells,
14,24,25 we utilized an invasive and angiogenic
U251HF glioma model that more closely resembles human
gliomas and monitored the effects in vivo by real-time
imaging; AdsTRAIL caused tumor growth inhibition in this
relevant model, as demonstrated by bioluminescent imaging
studies. This effect also translated into a survival advantage
compared with the vector control, conﬁrming that tumor
inhibition was associated with durable clinical beneﬁt.
An added advantage of our vector system is the lesser
potential for antiviral immune responses compared with
replication-competent adenoviral vectors, which trigger
immune responses due to the large amounts of adenoviral
proteins they generate, limiting their beneﬁt.
Figure 7 Effects of combination of AdsTRAIL and newer anticancer agents on human organotypic glioma slices. Glioma slice cultures were established from freshly
resectedresidualglioblastomatissuederivedfromthreepatientsandtreatedwithAdsTRAILalone(100MOI)orincombinationwithtemozolomide(20mM),vorinostat(5mM),
and MG132 (10mM) for 24h and harvested as single-cell suspensions, which were further analyzed by ﬂow cytometry to identify the apoptosis sub-G1 fraction
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Cell Death and DiseaseOf particular relevance to human tumors, we tested the
effect of AdsTRAIL in an organotypic glioma slice culture
model derived from surgically resected human glioblastomas.
We demonstrated the induction of apoptosis in human glioma
slices by AdsTRAIL as shown by morphological changes and
caspase activation, which was not seen in slices treated with
vector control. These studies provide proof of concept that if
the adenoviral construct is delivered to the tumor, it can
transduce human glioma cells and induce apoptosis. To our
knowledge, this the ﬁrst time that live human glioma tissue
has been used ex vivo to demonstrate the effects of any
therapeutic agent, including, as in this study, TRAIL.
Activation of the TRAIL apoptotic pathway as a therapeutic
strategy against malignancies is currently under study in
clinical trials using the full-length ligand or humanized
antibodies that oligomerize and activate its death receptors.
The lack of local and systemic toxicity in our xenograft
experiments with improvement in survival suggests that the
apoptosis induction by sTRAIL is conﬁned to the tumor cells.
In addition, the results of our glioma slice culture model
provide strong support to the possibility that AdsTRAIL will
induce apoptosis in human gliomas; these data provide a
foundation for further assessment of sTRAIL as a therapeutic
agent against gliomas. This study also has limitations that will
require additional studies to be fully addressed; for instance,
the nude mouse xenograft model used in this study does not
test the efﬁcacy or toxicity of AdsTRAIL in an immunocompe-
tent system, which would be relevant to translational
strategies; however, studies in non-human primate models
22
and in recent clinical trials
26 have failed to show any immune-
related reactions to TRAIL. Another limitation is that the
glioma slice culture model used in this study examines the
effects of AdsTRAIL in a viable tissue system, but without a
circulatory component, and in the setting of culture conditions
that are different from the physiological environment. Addi-
tional studies are necessary, particularly with relevance to
factors that may modify the efﬁcacy of AdsTRAIL against
human gliomas. In this context, we have previously reported
that the balance between survival and death pathways are
important mediators of sensitivity to TRAIL. To enhance the
efﬁcacy of this agent, studies are ongoing to determine
whether rational targeting of survival pathways could syner-
gize with AdsTRAIL to generate potent antitumor effects
against gliomas.
Materials and Methods
Cells. Glioma cell lines were maintained in DMEM-F12 medium supplemented
with 10% fetal bovine serum (FBS) (Sigma Chemical Co., St. Louis, MO, USA).
NHAs (Clonetics, Walkersville, MD, USA) were grown in astrocyte growth medium
(Clonetics) containing 3% FBS, 0.02mg/ml human epidermal growth factor,
25mg/ml insulin, 0.025mg/ml progesterone, 50mg/ml transferrin, 50.0mg/ml
gentamicin, and 0.05mg/ml amphotericin B. hMSC cells were cultured in
mesenchymal stem cell growth medium (Cambrex/Clonetics) according to the
manufacturer’s directions. HEK293 and CP cells were grown in DMEM with 10%
FBS. All cells were cultured in a humidiﬁed atmosphere at 371C with 5% CO2.
Glioma cell lines were authenticated by short tandem repeat DNA ﬁngerprinting in
the brain tumor center core facility. Experiments were conducted within a year of
obtaining the cell lines to ensure the authenticity of the cell lines used.
Reagents. sTRAIL was purchased from Biomol Inc. (Plymouth Meeting, PA,
USA). Anti-TRAIL (CT)/Apo-2L was purchased from Axxora, LLC (San Diego, CA,
USA). Antibodies to caspase 8 (Ab-3) and PARP (Ab-2) were purchased from
Calbiochem (San Diego, CA, USA), and to caspase 3 from Cell Signaling(Danvers,
MA, USA).
Plasmid and adenovirus generation. The extracellular portion of the
TRAIL (representing sTRAIL, amino acids 95–281) was obtained by polymerase
chain reaction (PCR) ampliﬁcation using the full-length gene in an adenoviral
construct (Adg/TRAIL, kindly provided by Dr. Bingliang Fang, the University of
TexasMDAndersonCancerCenter,Houston,TX,USA),
27usingtheforwardprimer
50-GATATCGCCACCATGACCTCTGAGGAAACCATTTCTACAGTTCAA-30, and
the reverse primer 50-AAGAATTCGGATCCTTAGCCAACTAAAAAGGCCCCG-30.
ThePCRfragmentswereinitiallysubclonedintopCRII-TOPO(Invitrogen,Carlsbad,
CA, USA), and subsequently released from vector with EcoRV and EcoRI digestion
for subcloning into matching sites of plasmid ptop2 (Somatix Therapy Corporation,
Alameda, CA, USA), to derive the plasmid ptop2.sTRAIL (Supplementary Figure
2A). To avoid the potential toxicity of sTRAIL protein to the packaging cells, the CP
system, whichinhibits expressionof thetransgene, was used for theconstruction of
AdsTRAIL adenovirus (under a CMV promoter). Brieﬂy, the c5 (adenoviral
sequence donor)
28 and ptop2.sTRAIL DNA, following digestion with restriction
enzyme Sﬁ1, were co-transfected into CP cells using FuGene 6 reagent (Roche,
Indianapolis, IN, USA). The cells were harvested when an apparent viral cytopathic
effect was observed at about 8–10 days post-transfection. Cell lysate was prepared
by ﬁve cycles of freeze–thawing, and was used to sequentially infect the CP cells
twice. Finally, crude viral lysate was obtained to isolate individual plaques. Positive
plaqueswere identiﬁedby PCR andrestrictionanalysis(Supplementary Figure2B).
Recombinant virus was propagated in CP cells and was puriﬁed according to a
previously described method.
29 Puriﬁed virus was dialyzed, titered by standard
plaque assay, and stored at  801C. AdEGFP virus was generated as previously
described.
29 Expression of sTRAIL by the viral construct was conﬁrmed after
transduction into glioma cells and was detectable as early as 24h after viral
transduction (Supplementary Figure 2C).
Bystander effect assay. To determine whether TRAIL can be produced by
carriercellsandinducesabystandereffectinmalignantcells,atranswellassaywas
performed with 5 10
5 TRAIL-resistant hMSC cells per well in the upper chamber
insert of a six-well transwell plate with 0.4mm pores (Corning Inc., Lowell, MA,
USA). At 16h after seeding, the cells were transduced at 50 MOI of AdEGFP or
AdsTRAIL plus 5 MOI of AdEGFP. Cells were washed three times with 1  PBS 4h
post-infection,andallowedtogrowfor24h.Theupperchamberinsertwithtransduced
hMSC cells was then transferred onto the lower chamber with non-transduced
U251HFcells.Afteranadditional48h,thecellsinboththeupperandlowerchambers
were photographed with a ﬂuorescence microscope and subsequently harvested and
analyzed for apoptosis and cell cycle effects by ﬂow cytometry.
Immunoblot analysis. Cells were harvested at 24, 48, and 72h following
transductionwithAdsTRAILorAdEGFPatanMOIof100,andlysedwithRIPAlysis
buffer (50mM Tris-HCI pH 7.4, 150mM NaCl, 1.0% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, and 2mM EDTA) with1:100 protease inhibitor mixture
(Sigma ChemicalCo.)at 01C for 30min. Cell debriswas removedby centrifugation,
and supernatants were boiled in 1:1 Laemmli sample buffer (Bio-Rad, Hercules,
CA, USA) with 5% 2-mercaptoethanol. After protein concentration was determined
by the Bio-Rad Protein Assay (Bio-Rad), 30mg of protein was loaded per lane and
separated on 12% SDS-PAGE. The membranes were blocked in TBST (containing
5% non-fat milk, 0.05% Tween 20) for 1h, incubated at 41C overnight with the
appropriate primary antibodies, washed, and subsequently incubated with horse-
radish peroxidase-coupled secondary antibodies for 1h at room temperature.
Protein bands were visualized using ECL (Pierce, Rockford, IL, USA).
Viability assay. Five-thousand cells (NHAs, U373, LN229, U87, SNB19, D54
and HFU251)were plated per well in 96-wellmicroplates in a ﬁnal volume of 100ml/
well. On the following day, cells were treated with AdsTRAIL at an MOI of 100 (with
AdEGFP as control) and viability determined at 24, 48 and 72h using the WST
assay. Brieﬂy, 10ml per well of WST-1 reagent was added to each well and
incubated for 3h in a humidiﬁed atmosphere (371C, 5% CO2) as per the
manufacturer’s protocol (Roche). The OD value was measured using a microplate
reader (Spectra Max 190, Sunnyvale, CA, USA) at a wavelength of 450nm.
Flow cytometry. Early apoptosis cells were detected using the Annexin V-PI
(propidium iodide) apoptosis kit (BD Pharmingen, San Jose, CA, USA). Cells were
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washed with PBS. The cells were then resuspended in binding buffer, stained with
annexin V (0.6mg/ml) and PI (5mg/ml) for 15min in dark at room temperature, and
analyzed by two-color ﬂow cytometry. The sub-G1 fraction (representing apoptotic
cells) was also determined after transduction with virus and staining with PI (Sigma
Chemical Co.) using FACS Calibur cytometer and Cell Quest Pro Software (Becton
Dickinson, San Jose, CA, USA).
Clonogenic assay. To determine their anchorage-independent growth
capability, cells were trypsinized for 24h, following infection with 100 MOI of
AdsTRAIL or AdEGFP, and suspended at a concentration of 1000 cells/ml in
agarose gel (20% FBS, DMEM-F12, and 0.3% agarose). The mixture of cells and
agarose gel (2ml) was immediately plated over a base layer of agarose gel
(20% FBS, DMEM-F12, and 0.8% agarose), followed by incubation at 371Ci na
humidiﬁed atmosphereof 95% airand 5% CO2 for 2 weeksto allowtheformation of
macroscopic colonies. The mean number of colonies per high power ﬁeld (hpf) was
determined by counting the number of colonies in at least 10 hpf for each condition
using phase-contrast microscopy.
Immunohistochemistry. Parafﬁn-embedded tissue slices were processed
to generate 5mm tissue slides, which were used for H&E staining and to study the
downstream effects of sTRAIL. Apoptosis was determined using the Dead End
Colorimetric TUNEL Assay (Promega Corporation, Madison, WI, USA). Cleaved
caspase 3 (Cell Signaling, Danvers, MA, USA) and Hexon (using goat anti-
adenovirus polyclonal antibodies, Chemicon, Temecula, CA, USA) staining was
performed according to the manufacturer’s protocol for these products.
Human glioma organotypic slice culture. Fresh tumor tissue
specimens were obtained after surgical resections of glioblastoma multiforme
from the patient in our institution, who had formally consented to participate in this
study under a protocol approved by the Institutional Review Board. The fresh tissue
was immediately put into the ice-cold cutting solution (110mM sucrose, 60mM
NaCl, 3mM KCl, 1.25mM NaH2PO4, 28mm NaHCO3, 0.5mM CaCl2,5 m M
D-glucose, and 0.6mM ascorbate), which had been saturated with 95% O2 and 5%
CO2 (carbogen) and transferred to the laboratory. Viable tumor tissue slices
(0.5cm 0.5cm 300mm) were generated by adapting a well-established
hippocampal slice culture protocol using a Vibratome 3000 (Vibratome, St. Louis,
MO, USA), which uses a vibrating blade to separate cell layers instead of cutting
through tissue, allowing sectioning of soft viable tissue.
17 The tumor slices (5 slices
per condition in each experiment) were allowed to equilibrate in a mixture of 50%
cutting solution and 50% artiﬁcial CSF solution (125mM NaCl, 2.5mm KCl,
1.24mM NaH2PO4, 25mM NaHCO3,1 0 m MD-glucose, 2mM CaCl, and 1mM
MgCl2) for 30min, and transferred into growth medium (DMEM-F12 with 20% FBS
and antibiotic/antimycotic solution) at 371C. The tissues were transduced 2h later
with AdsTRAIL or AdEGFP at 100 MOI. Tissue slices were harvested 24, 48, and
72h after infection, ﬁxed in 10% formalin for 24h, and then transferred to 70%
ethanol.
Glioma xenograft experiments. Animal experiments were conducted
under a protocol approved by the Institutional Animal Safety Committee in
compliance with the Humane Care and Use of Laboratory Animals Policy. To
determine the in vivo effects of AdsTRAIL, a previously described nude mouse
intracranial glioma xenograft model was utilized.
16 This method utilizes a guide-
screw to direct the implantation of both tumor cells for generating the xenograft and
for the delivery of the therapeutic agent through the same guide-screw, resulting in
efﬁcient and highly accurate intratumoral delivery of the agent used. U251HF or
SNB19gliomacells,whichforminvasivetumors,wereimplantedat10
6cells/5mlvia
the guide-screw into the forebrain of 6-week-old female Nu/Nu mice. After 2 weeks,
to allow for tumor formation, AdsTRAIL, AdEGFP, or PBS (vehicle control) was
injected intratumorally through the guide-screw weekly for 4 weeks. A subset of
animals (3 animals/condition) were killed at day 3 following the ﬁrst adenoviral
injection to examine their histological features, induction of apoptosis, and viral
protein expression. In these animals, the brain was formalin ﬁxed and parafﬁn
embedded to generate slides for immunohistochemical studies. The remaining
animals were monitored and killed when morbid. Survival was analyzed by the
Kaplan–Meier method and the differences between subgroups were determined
using the log rank analysis.
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